ClinicalTrials.gg
Drug

Oxytocin clinical trials

Also written Syntocinon, Pitocin and TNX-1900.

Includes 1 study of Oxytocin citrate.

studies test it
494
open now
51
in phase 3
41
first study started
2002

How each study uses Oxytocin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Oxytocin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Apr 1980 · SYNTOCINON · NDA 018245 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Oxytocin
315
Intranasal Oxytocin
49
Oxytocin nasal spray
40
Syntocinon nasal spray
10
Intravenous oxytocin
8

Brand

Syntocinon
102
Pitocin
94
Syntocinon 24 IU
1

Development codes

TNX-1900
2
TI-001
1

Studies by the year they started

494 studies that test it; most in 2016 (49)

Studies that test Oxytocin, by start year
YearStudies
20021
20031
20056
20063
20075
20089
200916
201019
201121
201229
201329
201442
201540
201649
201739
201826
201926
202019
202117
202220
202326
202424
202516
202611

By phase

A phase 1/2 study counts in both.

Early Phase 1
38
Phase 1
66
Phase 2
144
Phase 3
41
Phase 4
53
No phase
180

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 478

University of Electronic Science and Technology of China (48) · Samuel Lunenfeld Research Institute, Mount Sinai Hospital (23) · Wake Forest University Health Sciences (20) · Massachusetts General Hospital (14) · University Hospital, Bonn (14) · Medical University of South Carolina (12) · University of North Carolina, Chapel Hill (12) · Cairo University (12)

Often tested with

Tested in the same studies.

Misoprostol (22) · Carbetocin (21) · Arginine Vasopressin (11) · Tranexamic Acid (5) · Dinoprostone (3) · Propranolol (2) · Lorazepam (2) · Mifepristone (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 21, 1 in phase 3

Studies that test Oxytocin, phase 3 first.

Studies

Open first, then newest update. How each study uses Oxytocin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 494

See all 494 studies that test Oxytocin →

Given beside what is tested · 35 — Oxytocin is usual care or a partner of the new treatment

Showing 20 of 35.

As the comparator · 32 — what is tested is compared with Oxytocin

Showing 20 of 32.

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call Oxytocin · ClinicalTrials.gg INT007945

  • MeSH (NLM) D010121OxytocinOne source ClinicalTrials.gov
  • UNII (FDA) 1JQS135EYNOXYTOCINOne source FDA
  • RxNorm 7824One source FDA
  • NCI Thesaurus C724Recombinant OxytocinOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.